OrbiMed’s Bristol-Myers Squibb BMY Stock Holding History

OrbiMed’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-500,000	Closed	-$22.7M	–	124
2019 Q2	$22.7M	Buy	+500,000	New	+$23.3M	0.35%	64
2018 Q2	–	Sell	-200,000	Closed	-$12.7M	–	149
2018 Q1	$12.7M	Buy	+200,000	New	+$12.9M	0.16%	97
2017 Q4	–	Sell	-150,000	Closed	-$9.56M	–	134
2017 Q3	$9.56M	Buy	+150,000	New	+$8.76M	0.09%	108
2017 Q2	–	Sell	-100,000	Closed	-$5.44M	–	140
2017 Q1	$5.44M	Buy	+100,000	New	+$5.48M	0.06%	114
2016 Q4	–	Sell	-100,000	Closed	-$5.39M	–	134
2016 Q3	$5.39M	Buy	+100,000	New	+$6.42M	0.06%	115
2015 Q3	–	Sell	-500,000	Closed	-$33.3M	–	135
2015 Q2	$33.3M	Sell	500,000 -500,000	-50%	-$33M	0.28%	66
2015 Q1	$64.5M	Buy	1,000,000 +750,000	+300%	+$47M	0.55%	52
2014 Q4	$14.8M	Sell	250,000 -50,000	-17%	-$2.82M	0.14%	86
2014 Q3	$15.4M	Buy	+300,000	New	+$15M	0.16%	85
2014 Q2	–	Sell	-750,000	Closed	-$39M	–	136
2014 Q1	$39M	Buy	750,000 +200,000	+36%	+$10.6M	0.48%	48
2013 Q4	$29.2M	Buy	550,000 +300,000	+120%	+$15.3M	0.43%	50
2013 Q3	$11.6M	Sell	250,000 -50,000	-17%	-$2.19M	0.21%	69
2013 Q2	$13.4M	Buy	+300,000	New	+$13M	0.28%	62

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's BMY Position: Q1 2026 in Review

OrbiMed increased its Bristol-Myers Squibb (BMY) stake by 19% in Q1 2026, buying an estimated $8.74M and bringing the position to 925,000 shares worth $56.1M. The position accounts for 1.11% of the portfolio, ranked #25.

OrbiMed first reported a position in BMY in Q2 2013 and has held it in 42 quarters since. The position peaked at $577M in Q4 2015. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

OrbiMed held 925,000 shares of Bristol-Myers Squibb worth $56.1M as of Q1 2026.
OrbiMed bought 150,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.74M.
Bristol-Myers Squibb made up 1.11% of OrbiMed's portfolio in Q1 2026, its #25 holding.
OrbiMed first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 42 quarters since.
OrbiMed's Bristol-Myers Squibb position peaked at $577M in Q4 2015.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.